Role of Efflux in Antibiotic Resistance of Achromobacter xylosoxidans and Achromobacter insuavis Isolates From Patients With Cystic Fibrosis.

Chalhoub H, Kampmeier S, Kahl BC, Van Bambeke F

Research article (journal) | Peer reviewed

Abstract

Abstract Achromobacter genus (including Achromobacter xylosoxidans, the most prevalent Achromobacter species in patients with cystic fibrosis) is poorly susceptible to most conventional antibiotics. Contribution of efflux by AxyABM, AxyXY-OprZ, and AxyEF-OprN and of target mutations were studied in clinical isolates of A. xylosoxidans and Achromobacter insuavis. Forty-one isolates longitudinally collected from 21 patients with CF were studied by whole-genome sequencing (WGS)-typing, determination of minimum inhibitory concentrations (MICs) of β-lactams, aminoglycosides, colistin, azithromycin, ciprofloxacin, chloramphenicol, and doxycycline, and expression (quantitative RT-PCR) and function (measure of the uptake of a fluorescent substrate) of efflux pumps. WGS-based typing resulted in 10 clusters comprising 2 or 3 isolates and 20 singletons. The efflux activity was high in strains with elevated MICs for amikacin or azithromycin. This work sheds a new light on the impact of efflux and target mutations in resistance of Achromobacter to several drugs.

Details about the publication

JournalFrontiers in Microbiology (Front Microbiol)
Volume13
Page range762307null
StatusPublished
Release year2022 (28/03/2022)
Language in which the publication is writtenEnglish
DOI10.3389/fmicb.2022.762307
KeywordsAchromobacter; aminoglycoside; efflux; fluoroquinolone; macrolide; target mutation

Authors from the University of Münster

Kahl, Barbara
Institute of Medical Microbiology
Kampmeier, Stefanie
Institute of Hygiene